2-(2-amino-pyrimidin-4-yl)-1-methyl-4-oxo-3-{3-[3-(4-trifluoromethyl-phenyl)-ureido]-benzyl}-1,4,6,7-tetrahydro-pyrrolo[3,2-c]pyridine-5-carboxylic acid tert-butyl ester | 1258961-87-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(2-amino-pyrimidin-4-yl)-1-methyl-4-oxo-3-{3-[3-(4-trifluoromethyl-phenyl)-ureido]-benzyl}-1,4,6,7-tetrahydro-pyrrolo[3,2-c]pyridine-5-carboxylic acid tert-butyl ester
• 英文别名: tert-butyl 2-(2-aminopyrimidin-4-yl)-1-methyl-4-oxo-3-[[3-[[4-(trifluoromethyl)phenyl]carbamoylamino]phenyl]methyl]-6,7-dihydropyrrolo[3,2-c]pyridine-5-carboxylate
• CAS: 1258961-87-3
• 化学式: C₃₂H₃₂F₃N₇O₄
• 分子量: 635.646
• InChiKey: MBBKLFIEARJAOC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  46
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  145
• 氢给体数：
  3
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  1-异氰基-4-三氟甲基苯 、 3-(3-amino-benzyl)-2-(2-amino-pyrimidin-4-yl)-1-methyl-4-oxo-1,4,6,7-tetrahydro-pyrrolo[3,2-c]pyridine-5-carboxylic acid tert-butyl ester 、 甲基叔丁基醚 在 氩 、 水 、 Brine 、 Sodium sulfate-III 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 以affording 2-(2-Amino-pyrimidin-4-yl)-1-methyl-4-oxo-3-{3-[3-(4-trifluoromethyl-phenyl)-ureido]-benzyl}-1,4,6,7-tetrahydro-pyrrolo[3,2-c]pyridine-5-carboxylic acid tert-butyl ester (0.051 g, 0.080 mmol, 93%)的产率得到2-(2-amino-pyrimidin-4-yl)-1-methyl-4-oxo-3-{3-[3-(4-trifluoromethyl-phenyl)-ureido]-benzyl}-1,4,6,7-tetrahydro-pyrrolo[3,2-c]pyridine-5-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and their use as kinase inhibitors

  摘要：

  本发明公开了式（I）中定义的嘧啶基吡咯吡啶酮衍生物及其药学上可接受的盐，以及它们的制备方法和包含它们的制药组合物；该发明的化合物可能在治疗与蛋白激酶活性失调相关的疾病，如癌症中有用。

  公开号：

  US08546413B2

文献信息

• [EN] SUBSTITUTED PYRIMIDINYLPYRROLOPYRIDINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE PYRIMIDINYLPYRROLOPYRIDINONE SUBSTITUÉS, PROCÉDÉ POUR LEUR PRÉPARATION ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE KINASE
  申请人：NERVIANO MEDICAL SCIENCES SRL

  公开号：WO2010145998A1

  公开（公告）日：2010-12-23

  Pyrimidinylpyrrolopyridinone derivatives of formula (I) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.

  公开了规范中定义的式（I）的嘧啶基吡咯吡啶酮衍生物及其药学上可接受的盐，其制备方法以及包含它们的药物组合物；本发明的化合物可能在治疗中对与蛋白激酶活性失调有关的疾病，如癌症，具有用处。
• SUBSTITUTED PYRIMIDINYLPYRROLOPYRIDINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS
  申请人：Marchionni Chiara

  公开号：US20120178770A1

  公开（公告）日：2012-07-12

  Pyrimidinylpyrrolopyridinone derivatives of formula (I) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.

  本发明公开了式（I）中定义的嘧啶基吡咯吡啶酮衍生物及其药学上可接受的盐，以及制备它们的方法和包含它们的制药组合物；该发明的化合物可能在治疗与蛋白激酶活性失调有关的疾病，如癌症中有用。
• US8546413B2
  申请人：——

  公开号：US8546413B2

  公开（公告）日：2013-10-01
• US8969366B2
  申请人：——

  公开号：US8969366B2

  公开（公告）日：2015-03-03
• Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and their use as kinase inhibitors
  申请人：Marchionni Chiara

  公开号：US08969366B2

  公开（公告）日：2015-03-03

  Pyrimidinylpyrrolopyridinone derivatives of formula (I) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.

  本发明揭示了式（I）中定义的嘧啶基吡咯吡啶酮衍生物及其药学上可接受的盐，其制备过程和包含它们的制药组合物；本发明的化合物可能在治疗与蛋白激酶活性失调有关的疾病，如癌症方面有用。